Central serous chorioretinopathy: Current update on management

George Joseph Manayath, Ratnesh Ranjan, Smita S Karandikar, Vanee Sheth Shah, Veerappan R Saravanan, Venkatapathy Narendran, George Joseph Manayath, Ratnesh Ranjan, Smita S Karandikar, Vanee Sheth Shah, Veerappan R Saravanan, Venkatapathy Narendran

Abstract

Central serous chorioretinopathy (CSC), the fourth most common nonsurgical retinopathy with a usual self-limiting course, is known to present with persistent or recurrent form with distressing visual loss. Evolution of newer mutimodal imaging techniques have revolutionized the understanding about the pathophysiology of CSC, and hence the diagnosis and management. Multifactorial etiopathology of CSC promotes the use of multiple treatment modalities. With advances in investigative options, treatment options including conventional focal laser, micropulse laser, photodynamic therapy, and transpupillary thermotherapy are also advancing and refining. Medical management for CSC is also under evaluation with a wide spectrum of new drugs in vogue. However, standard of treatment is yet to be established through randomized clinical trials. This review article discusses the current approach to multimodal treatment options for CSC including conventional as well as newer therapeutic modalities.

Keywords: Anti-vascular endothelial growth factor vascular endothelial growth factor; central serous chorioretinopathy; epleneroneeplenerone; micropulse laser; photodynamic therapy; transpupillary thermotherapy.

Conflict of interest statement

There are no conflicts of interest.

References

    1. Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86:126–45.
    1. Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: Update on pathophysiology and treatment. Surv Ophthalmol. 2013;58:103–26.
    1. Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P. Interventions for central serous chorioretinopathy: A network meta-analysis. Cochrane Database Syst Rev. 2015;12:CD011841.
    1. Ratanasukon M, Bhurayanontachai P, Jirarattanasopa P. High-dose antioxidants for central serous chorioretinopathy; the randomized placebo-controlled study. BMC Ophthalmol. 2012;12:20.
    1. Hofstetter W, Griffin J, Berman M, Everson R. Visual Science and Related Clinical Terms. Vol. 5. Woburn: Butterworth-Heinemann; 2000.
    1. Mitsui Y, Matsubara M, Kanagawa M. Xenon light-exposure as a treatment of central serous retinopathy (a preliminary report) Nihon Ganka Kiyo. 1969;20:291–4.
    1. Leaver P, Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1979;63:674–7.
    1. Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983;95:457–66.
    1. Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol. 1984;68:815–20.
    1. Ficker L, Vafidis G, While A, Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1988;72:829–34.
    1. Brancato R, Bandello F. Treatment of central serous chorioretinopathy with beta-blockers and calcium antagonists. Macula Soc. 1994;3:114.
    1. Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: Results of long-term follow-up. Ophthalmology. 1997;104:616–22.
    1. Sivaprasad S, Elagouz M, McHugh D, Shona O, Dorin G. Micropulsed diode laser therapy: Evolution and clinical applications. Surv Ophthalmol. 2010;55:516–30.
    1. Roisman L, Magalhães FP, Lavinsky D, Moraes N, Hirai FE, Cardillo JA, et al. Micropulse diode laser treatment for chronic central serous chorioretinopathy: A randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina. 2013;44:465–70.
    1. Verma L, Sinha R, Venkatesh P, Tewari HK. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: A pilot, randomized controlled trial [ISRCTN84128484] BMC Ophthalmol. 2004;4:15.
    1. Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115:2229–34.
    1. Ricci F, Missiroli F, Cerulli L. Indocyanine green dye-enhanced micropulsed diode laser: A novel approach to subthreshold RPE treatment in a case of central serous chorioretinopathy. Eur J Ophthalmol. 2004;14:74–82.
    1. Yadav NK, Jayadev C, Mohan A, Vijayan P, Battu R, Dabir S, et al. Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: Safety profile and treatment outcome. Eye (Lond) 2015;29:258–64.
    1. Özmert E, Demirel S, Yanık Ö, Batıoğlu F. Low-fluence photodynamic therapy versus subthreshold micropulse yellow wavelength laser in the treatment of chronic central serous chorioretinopathy. J Ophthalmol. 2016;2016:3513794.
    1. Scholz P, Altay L, Fauser S. Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Lond) 2016;30:1371–7.
    1. Schlötzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:748–57.
    1. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: One-year results of a randomized controlled trial. Ophthalmology. 2008;115:1756–65.
    1. Ruiz-Moreno JM, Lugo FL, Armadá F, Silva R, Montero JA, Arevalo JF, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol. 2010;88:371–6.
    1. Moon JW, Yu HG, Kim TW, Kim HC, Chung H. Prognostic factors related to photodynamic therapy for central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247:1315–23.
    1. Abouammoh MA. Advances in the treatment of central serous chorioretinopathy. Saudi J Ophthalmol. 2015;29:278–86.
    1. Lim JW, Kang SW, Kim YT, Chung SE, Lee SW. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. Br J Ophthalmol. 2011;95:514–7.
    1. Zhao MW, Zhou P, Xiao HX, Lv YS, Li CA, Liu GD, et al. Photodynamic therapy for acute central serous chorioretinopathy: The safe effective lowest dose of verteporfin. Retina. 2009;29:1155–61.
    1. Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: A nonrandomized clinical trial. Am J Ophthalmol. 2010;149:307–1500.
    1. Nicoló M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2014;157:1033–7.
    1. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: A pilot study. Retina. 2003;23:288–98.
    1. Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: Photodynamic therapy. Am J Ophthalmol. 2004;137:1073–80.
    1. Shukla D, Kolluru C, Vignesh TP, Karthikprakash S, Kim R. Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy. Eye (Lond) 2008;22:100–6.
    1. Manayath GJ, Narendran V, Arora S, Morris RJ, Saravanan VR, Shah PK, et al. Graded subthreshold transpupillary thermotherapy for chronic central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging. 2012;43:284–90.
    1. Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F, et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: A pilot study. Retina. 2013;33:2096–102.
    1. Grieshaber MC, Staub JJ, Flammer J. The potential role of testosterone in central serous chorioretinopathy. Br J Ophthalmol. 2007;91:118–9.
    1. Golshahi A, Klingmüller D, Holz FG, Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: A pilot study. Acta Ophthalmol. 2010;88:576–81.
    1. Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina. 2011;31:1928–36.
    1. Steinle NC, Gupta N, Yuan A, Singh RP. Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. Br J Ophthalmol. 2012;96:10–3.
    1. Singh RP, Sears JE, Bedi R, Schachat AP, Ehlers JP, Kaiser PK, et al. Oral eplerenone for the management of chronic central serous chorioretinopathy. Int J Ophthalmol. 2015;8:310–4.
    1. Jampol LM, Weinreb R, Yannuzzi L. Involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: A rationale for new treatment strategies. Ophthalmology. 2002;109:1765–6.
    1. Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina. 2007;27:943–6.
    1. Clark JA, Flick RB, Pai LY, Szalayova I, Key S, Conley RK, et al. Glucocorticoid modulation of tryptophan hydroxylase-2 protein in raphe nuclei and 5-hydroxytryptophan concentrations in frontal cortex of C57/Bl6 mice. Mol Psychiatry. 2008;13:498–506.
    1. Ravage ZB, Packo KH, Creticos CM, Merrill PT. Chronic central serous chorioretinopathy responsive to rifampin. Retin Cases Brief Rep. 2012;6:129–32.
    1. Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB, et al. Finasteride for chronic central serous chorioretinopathy. Retina. 2011;31:766–71.
    1. Ahad MA, Chua CN, Evans NM. Central serous chorioretinopathy associated with testosterone therapy. Eye (Lond) 2006;20:503–5.
    1. Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122:2672–9.
    1. Delyani JA. Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology. Kidney Int. 2000;57:1408–11.
    1. Sampo M, Soler V, Gascon P, Ho Wang Yin G, Hoffart L, Denis D, et al. Eplerenone treatment in chronic central serous chorioretinopathy. J Fr Ophtalmol. 2016;39:535–42.
    1. Rahimy E, Pitcher JD, 3rd, Hsu J, Adam MK, Shahlaee A, Samara WA, et al. A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ecselsior) Retina. 2018;38:962–9.
    1. Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S, et al. Eplerenone for chronic central serous chorioretinopathy – A randomized controlled prospective study. Acta Ophthalmol. 2017;95:e610–8.
    1. Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol. 1988;106:1190–5.
    1. Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109:1723–5.
    1. Ontiveros-Orozco I, Garcia-Franco R, Levine-Berebichez A, Celis-Suazo B, Rojas-Juarez S. Topical brinzolamide for the treatment of idiopathic central serous chorioretinopathy. Invest Ophthalmol Vis Sci. 2004;45:529.
    1. Giusti C. Association of Helicobacter pylori with central serous chorioretinopathy: Hypotheses regarding pathogenesis. Med Hypotheses. 2004;63:524–7.
    1. Cotticelli L, Borrelli M, D'Alessio AC, Menzione M, Villani A, Piccolo G, et al. Central serous chorioretinopathy and Helicobacter pylori. Eur J Ophthalmol. 2006;16:274–8.
    1. Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, Rafeey M, Ghorbanihaghjo A. The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis. 2011;17:99–103.
    1. Dang Y, Mu Y, Zhao M, Li L, Guo Y, Zhu Y, et al. The effect of eradicating Helicobacter pylori on idiopathic central serous chorioretinopathy patients. Ther Clin Risk Manag. 2013;9:355–60.
    1. Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol. 2010;24:155–8.
    1. Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011;152:784–92.e2.
    1. Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina. 2010;30:100–6.
    1. Lee ST, Adelman RA. The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab. J Ocul Pharmacol Ther. 2011;27:611–4.
    1. Ji S, Wei Y, Chen J, Tang S. Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: A meta-analysis. Int J Clin Pharm. 2017;39:514–21.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren